Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow NEOGENOMICS INC

Get SEC filing alerts via email and in your feed for NEOGENOMICS INC

NEO

NEOGENOMICS INC

About NEOGENOMICS INC

NeoGenomics, Inc. specializes in oncology diagnostic testing and consultative services, including molecular, cytogenetic, and histopathology analyses. Operating laboratories in the U.S. and U.K., it serves healthcare providers, pharmaceutical companies, and research institutions. The company offers comprehensive cancer testing, interpretation, and data solutions, leveraging advanced technologies like NGS and liquid biopsies to support personalized medicine and drug development. Its core focus is improving patient outcomes through high-quality, innovative cancer diagnostics.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from NEOGENOMICS INC

1
1
NEOGENOMICS INC NeoGenomics Reports $186.7 Million Revenue in Q1 2026, Up 11.1%

Via official filing (AI summary) | about 2 months ago | 0 comments

2
1
NEOGENOMICS INC NeoGenomics Reports 10.1% Revenue Growth to $727.3 Million, Faces Increased Net Loss

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
NEOGENOMICS INC NeoGenomics Reports 11.9% Revenue Growth to $187.8 Million in Q3 2025

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
NEOGENOMICS INC NeoGenomics Reports $181.3 Million Revenue in Q2 2025, Net Loss of $45.1 Million

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
NEOGENOMICS INC NeoGenomics Reports $168M Revenue and $25.9M Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
NEOGENOMICS INC NeoGenomics Reports 11.6% Revenue Increase to $660.6 Million for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
NEOGENOMICS INC Negeneomics Reports 10.4% Revenue Growth, Net Loss Improvement in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments